Data | Hora | Fonte | Título | Código | Companhia |
12/11/2007 | 19:00 | PR Newswire (US) | Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
07/11/2007 | 19:00 | PR Newswire (US) | Allos Therapeutics to Present at the 2007 JMP Securities Healthcare Focus Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
05/11/2007 | 17:02 | Edgar (US Regulatory) | Allos Therapeutics Inc - Quarterly Report (10-Q) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
05/11/2007 | 11:03 | Edgar (US Regulatory) | Allos Therapeutics Inc - Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
05/11/2007 | 10:30 | PR Newswire (US) | Allos Therapeutics Reports Third Quarter 2007 Financial Results | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
31/10/2007 | 10:00 | PR Newswire (US) | Allos Therapeutics to Present at the 2007 Acumen BioFin Rodman & Renshaw Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
25/10/2007 | 18:01 | PR Newswire (US) | Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
17/10/2007 | 18:58 | Edgar (US Regulatory) | Allos Therapeutics Inc - Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
16/10/2007 | 09:55 | PR Newswire (US) | Allos Therapeutics to Report 2007 Third Quarter Financial Results on November 5, 2007 | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
26/09/2007 | 11:43 | Edgar (US Regulatory) | Allos Therapeutics Inc (Other) (SC 13G) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
24/09/2007 | 16:35 | Edgar (US Regulatory) | Allos Therapeutics Inc (Other) (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
24/09/2007 | 08:30 | PR Newswire (US) | Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
13/09/2007 | 09:00 | PR Newswire (US) | Allos Therapeutics to Present at the 2007 UBS Global Life Sciences Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
04/09/2007 | 09:00 | PR Newswire (US) | Allos Therapeutics to Present at the Bear Stearns 20th Annual Healthcare Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
15/08/2007 | 09:00 | PR Newswire (US) | Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
07/08/2007 | 10:00 | PR Newswire (US) | Allos Therapeutics Reports Second Quarter 2007 Financial Results | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
18/07/2007 | 09:00 | PR Newswire (US) | Allos Therapeutics to Report 2007 Second Quarter Financial Results on August 7, 2007 | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
25/06/2007 | 10:30 | PR Newswire (US) | Allos Therapeutics Selected to Join Russel 3000 Index | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
19/06/2007 | 07:30 | PR Newswire (US) | Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
31/05/2007 | 18:01 | PR Newswire (US) | Allos Therapeutics Initiates Phase I/II Study of PDX and Gemcitabine in Patients With Non-Hodgkin's Lymphoma or Hodgkin's Diseas | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
23/05/2007 | 18:55 | PR Newswire (US) | Allos Therapeutics Files Shelf Registration Statement | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
08/05/2007 | 09:30 | PR Newswire (US) | Allos Therapeutics Reports First Quarter 2007 Financial Results | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
01/05/2007 | 14:21 | PR Newswire (US) | Allos Therapeutics to Announce 2007 First Quarter Results on Tuesday, May 8 | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
26/04/2007 | 09:00 | PR Newswire (US) | Allos Therapeutics Appoints Dr. Jeffrey R. Latts to Its Board of Directors | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
19/04/2007 | 09:30 | PR Newswire (US) | Allos Therapeutics' PDX Granted Orphan Medicinal Product Designation by the European Commission | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
20/03/2007 | 09:00 | PR Newswire (US) | Allos Therapeutics Appoints Pablo J. Cagnoni, M.D. as Chief Medical Officer | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
05/03/2007 | 09:00 | PR Newswire (US) | Allos Therapeutics Reports Fourth Quarter and 2006 Financial Results | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
27/02/2007 | 10:00 | PR Newswire (US) | Allos Therapeutics to Report 2006 Fourth Quarter Financial Results on Monday, March 5 | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
13/02/2007 | 11:00 | PR Newswire (US) | Allos Therapeutics to Present at Upcoming Investor Conferences | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
02/02/2007 | 14:01 | PR Newswire (US) | Allos Therapeutics Announces Closing of Common Stock Offering | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |